PXMD(Delisted)
PaxMedicaยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PXMD
Paxmedica, Inc.
A clinical stage biopharmaceutical company that develops novel anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms
303 South Broadway, Suite 125, Tarrytown, NY 10591
--
PaxMedica, Inc., was incorporated as a Delaware limited liability company on April 5, 2018 and converted to a Delaware corporation on April 15, 2020. The Company is an early clinical-stage biopharmaceutical company focused on the development of antipurinergic therapies (or APT) for the treatment of neurodevelopmental disorders, including autism spectrum disorder (ASD) and brittle X syndrome ataxia (FXTAS).
Company Financials
EPS
PXMD has released its 2023 Q3 earnings. EPS was reported at -5.2, versus the expected 0, missing expectations. The chart below visualizes how PXMD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
